PEGconjugated

PEGylation is a process in which polyethylene glycol (PEG), a biocompatible and water-soluble polymer, is attached to a molecule. This molecule can be a protein, peptide, small molecule drug, or nanoparticle. The attachment is typically done through a covalent bond. The resulting molecule is referred to as PEGconjugated.

PEGylation can significantly alter the properties of the parent molecule. For example, PEGconjugated drugs often exhibit a longer circulation half-life in the body due to reduced clearance by the kidneys and immune system. This is because the bulky PEG chain can shield the molecule from enzymatic degradation and recognition by antibodies. Furthermore, PEGylation can reduce immunogenicity, making therapeutic proteins less likely to provoke an adverse immune response. The increased solubility imparted by PEG can also be beneficial for hydrophobic drugs.

The PEG molecule itself is inert and has a low toxicity profile, making it suitable for biomedical applications. Different lengths and structures of PEG can be used to achieve varying degrees of modification. The attachment site and the specific linkage chemistry are critical aspects of the PEGylation process, influencing the stability and biological activity of the final PEGconjugated product. PEGconjugated therapeutics have found widespread use in treating a variety of conditions, including cancer, inflammatory diseases, and viral infections.